Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
WAGNER MARK T
  2. Issuer Name and Ticker or Trading Symbol
Alliqua BioMedical, Inc. [ALQA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O ALLIQUA BIOMEDICAL, INC., 2150 CABOT BLVD. WEST
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2015
(Street)

LANGHORNE, PA 19047
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/29/2015   A   174,033 (1) (2) A (2) 174,033 (1) (2) I By 2003 Revocable Trust of Mark Wagner (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 4.95 05/29/2015   A   15,000     (3) 05/29/2025 Common Stock 15,000 $ 0 15,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
WAGNER MARK T
C/O ALLIQUA BIOMEDICAL, INC.
2150 CABOT BLVD. WEST
LANGHORNE, PA 19047
  X      

Signatures

 /s/ Mark T. Wagner   06/02/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reported shares are owned directly by 2003 Revocable Trust of Mark Wagner dated April 23, 2003(the "Wagner Trust"). Mark Wagner is the trustee and deemed to have a pecuniary interest in, and therefore to be the beneficial owner of, shares held by the Wagner Trust. On May 29, 2015, Alliqua BioMedical, Inc. (the "Issuer") consummated a merger, pursuant to which Celleration, Inc. ("Celleration") merged with and into a wholly-owned subsidiary of the Issuer (the "Merger"). In connection with the Merger, the Wagner Trust acquired 174,033 shares of the Issuer's common stock in exchange for all outstanding shares of Celleration common stock and Series AA preferred stock held immediately prior to the effective time of the Merger.
(2) The Agreement and Plan of Merger, dated February 2, 2015 (the "Merger Agreement") placed a value on the Issuer's common stock of $4.80 per share, based on the trailing 45 trading day volume weighted average price as of the second trading day prior to the date of the Merger Agreement. Of the 174,033 shares issued to the Wagner Trust, 11,443 shares are currently being held in escrow and are subject to forfeiture during the eighteen month period following the closing of the Merger to satisfy certain claims and post-closing adjustments as provided in the Merger Agreement.
(3) The option vests in twelve equal monthly installments with one-twelfth (1/12) vesting on the twenty-ninth (29th) day of each of the next twelve months, with the first such vesting date occurring on June 29, 2015, provided that Mr. Wagner is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.